Welcome!

News Feed Item

PharmaPoint: Hemophilia A and B - China Drug Forecast and Market Analysis to 2022

NEW YORK, Jan. 16, 2014 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

PharmaPoint: Hemophilia A and B - China Drug Forecast and Market Analysis to 2022
http://www.reportlinker.com/p01957666/PharmaPoint-Hemophilia-A-and-B---China-Drug-Forecast-and-Market-Analysis-to-2022.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Pathology

PharmaPoint: Hemophilia A and B - China Drug Forecast and Market Analysis to 2022

Summary

The competitive landscape of hemophilia A and B recombinant therapy in the US and 5EU is dominated by the use of recombinant FVIII and FIX replacement factors, and patients with severe forms of the disease receive frequent prophylactic infusions beginning from the first one or two years of life and often continuing through adulthood. However, the burden on patients and their families to maintain the prophylactic treatment schedule is high, and there is a significant unmet need for new therapies that can reduce the number of weekly prophylactic infusions and alleviate some of this treatment burden.

Treatment options in China are extremely limited compared with the 7MM. Although some recombinant replacement therapies for hemophilia A and B, such as Recombinate, Xyntha, Kogenate, Advate and BeneFIX, are approved for marketing in China, they are not covered by national or provisional insurance programs and access to these drugs is extremely limited.

Scope

- Overview of Hemophilia A and B including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
- Detailed information on the key drugs in China including product description, safety and efficacy profiles as well as a SWOT analysis.
- Sales forecast for the top drugs in China from 2012-2022.
- Analysis of the impact of key events as well the drivers and restraints affecting China Hemophilia A and B market.

Reasons to buy

- Understand and capitalize by identifying products that are most likely to ensure a robust return
- Stay ahead of the competition by understanding the changing competitive landscape for Hemophilia A and B
- Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
- Make more informed business decisions from insightful and in-depth analysis of drug performance
- Obtain sales forecast for drugs from 2012-2022 in China
1 Table of Contents
1 Table of Contents 4
1.1 List of Tables 7
1.2 List of Figures 8
2 Introduction 9
2.1 Catalyst 9
2.2 Related Reports 10
2.3 Upcoming Related Reports 12
3 Disease Overview 13
3.1 Etiology and Pathophysiology 13
3.1.1 Etiology 13
3.1.2 Pathophysiology 14
3.1.3 Prognosis and Quality of Life 16

3.2 Symptoms 17
3.2.1 Hemophilia A and B 17
3.2.2 Inhibitors 18
4 Disease Management 19
4.1 Treatment Overview 19
4.1.1 Hemophilia A and B Diagnosis 20
4.1.2 Hemophilia A and B Treatment 20
4.1.3 Inhibitors Diagnosis 22
4.1.4 Inhibitors Treatment 22
4.2 China 24
4.2.1 Clinical Practice 24
5 Competitive Assessment 26
5.1 Overview 26
5.2 Strategic Competitive Assessment 27
5.3 Product Profiles - Major Brands, Hemophilia A 31
5.3.1 Advate (octocog alfa; Antihemophilic Factor [Recombinant] Plasma/Albumin-Free) 31
5.3.2 Kogenate FS/Helixate FS (Antihemophilic Factor (Recombinant)) 35
5.3.3 Recombinate (octocog alfa; Antihemophilic Factor [Recombinant] Plasma/Albumin-Free) 38
5.4 Product Profiles - Hemophilia B 40
5.4.1 BeneFIX (nonacog alfa; coagulation factor IX [recombinant]) 40
5.4.2 Rixubis (BAX-326) 43
5.5 Product Profiles - Hemophilia A and B with Inhibitors 46
5.5.1 NovoSeven RT (coagulation factor VIIa [recombinant]) 46

6 Opportunity and Unmet Need 48
6.1 Overview 48
6.2 Opportunities Analysis 49
6.2.1 Longer-Lasting Recombinant Factors to Reduce the Frequency of Prophylactic Injections 49
6.2.2 Lower-Cost Recombinant Replacement Therapies 50
6.2.3 Lower Risk of Inhibitor Formation in Previously Untreated Patients 51
6.2.4 More Convenient Drug Administration 51
6.2.5 Oral Formulation of Recombinant Replacement Therapies 52
6.3 Unmet Needs Gap Analysis 52
6.3.1 Long-Acting FVIII Replacement Therapies 52
6.3.2 Gene Therapy Treatments for Hemophilia A and B 53
7 Pipeline Assessment 54
7.1 Overview 54
7.2 Promising Drugs in Clinical Development - Hemophilia A 54
7.2.1 BAY 94-9027 (octocog alfa) 56
7.2.2 BAX-855 59
7.2.3 Novoeight (turoctocog alfa; NN7008) 63
7.2.4 N8-GP (NN7088) 66
8 Market Outlook 70
8.1 China 70
8.1.1 Forecast 70
8.1.2 Key Events 73
8.1.3 Drivers and Barriers 73
9 Appendix 75
9.1 Bibliography 75
9.2 Abbreviations 83

9.3 Methodology 86
9.4 Forecasting Methodology 86
9.4.1 Diagnosed Hemophilia Patients 87
9.4.2 Percent Drug-Treated Patients 87
9.4.3 Drugs Included in Each Therapeutic Class 88
9.4.4 Launch and Patent Expiry Dates 88
9.4.5 General Pricing Assumptions 89
9.4.6 Individual Drug Assumptions 89
9.4.7 Pricing of Pipeline Agents 92
9.5 Physicians and Specialists Included in this Study 93
9.6 About the Authors 95
9.6.1 Authors 95
9.6.2 Global Head of Healthcare 96
9.7 About GlobalData 97
9.8 Disclaimer 97

1.1 List of Tables

Table 1: Symptoms of Hemophilia A and B 18
Table 2: Most Prescribed Hemophilia A and B Drugs in the Global Markets, 2013 23
Table 3: Leading Recombinant Replacement Therapies for Hemophilia A and B and Patients with Inhibitors, 2013 29
Table 4: Leading Plasma-Based Replacement Therapies for Hemophilia A and B and Patients with Inhibitors, 2012 30
Table 5: Product Profile - Advate (octocog alfa; Antihemophilic Factor [Recombinant] Plasma/Albumin-Free) 32
Table 6: Advate SWOT Analysis, 2013 34
Table 7: Product Profile - Kogenate FS/Helixate FS (Antihemophilic Factor (Recombinant)) 36
Table 8: Kogenate FS/Helixate FS SWOT Analysis, 2013 38
Table 9: Product Profile - Recombinate (octocog alfa; Antihemophilic Factor [Recombinant] Plasma/Albumin-Free) 39

Table 10: Recombinate SWOT Analysis, 2013 40
Table 11: Product Profile - BeneFIX (nonacog alfa; coagulation factor IX [recombinant]) 41
Table 12: BeneFIX SWOT Analysis, 2013 42
Table 13: Product Profile - Rixubis (BAX-326) 44
Table 14: Rixubis SWOT Analysis, 2013 45
Table 15: Product Profile - NovoSeven RT (coagulation factor VIIa [recombinant]) 46
Table 16: NovoSeven RT SWOT Analysis, 2013 47
Table 17: Overall Unmet Needs - Current Level of Attainment 49
Table 18: Hemophilia A - Phase I/II Pipeline, 2013 54
Table 19: Hemophilia A - Phase III Pipeline, 2013 55
Table 20: Product Profile - BAY 94-9027 56
Table 21: BAY 94-9027 SWOT Analysis, 2013 59
Table 22: Product Profile - BAX-855 60
Table 23: BAX-855 SWOT Analysis, 2013 62
Table 24: Product Profile - Novoeight (turoctocog alfa; NN7008) 63
Table 25: Novoeight SWOT Analysis, 2013 66
Table 26: Product Profile - N8-GP (NN7088) 67
Table 27: N8-GP SWOT Analysis, 2013 69
Table 28: Sales Forecasts ($m) for Hemophilia A and B in China, 2012-2022 71
Table 29: Key Events Impacting Sales for Hemophilia A and B in China, 2013 73
Table 30: Chinese Hemophilia A and B Market - Drivers and Barriers, 2013 73
Table 31: Product Launch Dates 88
Table 32: Physicians Surveyed 93

1.2 List of Figures

Figure 1: Competitive Assessment of Late-Stage Pipeline Agents in Hemophilia A, 2012-2022 55
Figure 2: Sales for Hemophilia A and B in China by Drug Class, 2012-2022 72

To order this report: PharmaPoint: Hemophilia A and B - China Drug Forecast and Market Analysis to 2022
http://www.reportlinker.com/p01957666/PharmaPoint-Hemophilia-A-and-B---China-Drug-Forecast-and-Market-Analysis-to-2022.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Pathology

__________________________
Contact Clare: [email protected]
US: (339)-368-6001
Intl: +1 339-368-6001

SOURCE Reportlinker

More Stories By PR Newswire

Copyright © 2007 PR Newswire. All rights reserved. Republication or redistribution of PRNewswire content is expressly prohibited without the prior written consent of PRNewswire. PRNewswire shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

Latest Stories
Andrew Keys is Co-Founder of ConsenSys Enterprise. He comes to ConsenSys Enterprise with capital markets, technology and entrepreneurial experience. Previously, he worked for UBS investment bank in equities analysis. Later, he was responsible for the creation and distribution of life settlement products to hedge funds and investment banks. After, he co-founded a revenue cycle management company where he learned about Bitcoin and eventually Ethereal. Andrew's role at ConsenSys Enterprise is a mul...
The revocation of Safe Harbor has radically affected data sovereignty strategy in the cloud. In his session at 17th Cloud Expo, Jeff Miller, Product Management at Cavirin Systems, discussed how to assess these changes across your own cloud strategy, and how you can mitigate risks previously covered under the agreement.
Digital Initiatives create new ways of conducting business, which drive the need for increasingly advanced security and regulatory compliance challenges with exponentially more damaging consequences. In the BMC and Forbes Insights Survey in 2016, 97% of executives said they expect a rise in data breach attempts in the next 12 months. Sixty percent said operations and security teams have only a general understanding of each other’s requirements, resulting in a “SecOps gap” leaving organizations u...
In his session at 21st Cloud Expo, Raju Shreewastava, founder of Big Data Trunk, provided a fun and simple way to introduce Machine Leaning to anyone and everyone. He solved a machine learning problem and demonstrated an easy way to be able to do machine learning without even coding. Raju Shreewastava is the founder of Big Data Trunk (www.BigDataTrunk.com), a Big Data Training and consulting firm with offices in the United States. He previously led the data warehouse/business intelligence and Bi...
While some developers care passionately about how data centers and clouds are architected, for most, it is only the end result that matters. To the majority of companies, technology exists to solve a business problem, and only delivers value when it is solving that problem. 2017 brings the mainstream adoption of containers for production workloads. In his session at 21st Cloud Expo, Ben McCormack, VP of Operations at Evernote, discussed how data centers of the future will be managed, how the p...
Cell networks have the advantage of long-range communications, reaching an estimated 90% of the world. But cell networks such as 2G, 3G and LTE consume lots of power and were designed for connecting people. They are not optimized for low- or battery-powered devices or for IoT applications with infrequently transmitted data. Cell IoT modules that support narrow-band IoT and 4G cell networks will enable cell connectivity, device management, and app enablement for low-power wide-area network IoT. B...
Extreme Computing is the ability to leverage highly performant infrastructure and software to accelerate Big Data, machine learning, HPC, and Enterprise applications. High IOPS Storage, low-latency networks, in-memory databases, GPUs and other parallel accelerators are being used to achieve faster results and help businesses make better decisions. In his session at 18th Cloud Expo, Michael O'Neill, Strategic Business Development at NVIDIA, focused on some of the unique ways extreme computing is...
Transformation Abstract Encryption and privacy in the cloud is a daunting yet essential task for both security practitioners and application developers, especially as applications continue moving to the cloud at an exponential rate. What are some best practices and processes for enterprises to follow that balance both security and ease of use requirements? What technologies are available to empower enterprises with code, data and key protection from cloud providers, system administrators, inside...
The Internet of Things will challenge the status quo of how IT and development organizations operate. Or will it? Certainly the fog layer of IoT requires special insights about data ontology, security and transactional integrity. But the developmental challenges are the same: People, Process and Platform and how we integrate our thinking to solve complicated problems. In his session at 19th Cloud Expo, Craig Sproule, CEO of Metavine, demonstrated how to move beyond today's coding paradigm and sh...
With the proliferation of both SQL and NoSQL databases, organizations can now target specific fit-for-purpose database tools for their different application needs regarding scalability, ease of use, ACID support, etc. Platform as a Service offerings make this even easier now, enabling developers to roll out their own database infrastructure in minutes with minimal management overhead. However, this same amount of flexibility also comes with the challenges of picking the right tool, on the right ...
What are the new priorities for the connected business? First: businesses need to think differently about the types of connections they will need to make – these span well beyond the traditional app to app into more modern forms of integration including SaaS integrations, mobile integrations, APIs, device integration and Big Data integration. It’s important these are unified together vs. doing them all piecemeal. Second, these types of connections need to be simple to design, adapt and configure...
Traditional on-premises data centers have long been the domain of modern data platforms like Apache Hadoop, meaning companies who build their business on public cloud were challenged to run Big Data processing and analytics at scale. But recent advancements in Hadoop performance, security, and most importantly cloud-native integrations, are giving organizations the ability to truly gain value from all their data. In his session at 19th Cloud Expo, David Tishgart, Director of Product Marketing ...
More and more companies are looking to microservices as an architectural pattern for breaking apart applications into more manageable pieces so that agile teams can deliver new features quicker and more effectively. What this pattern has done more than anything to date is spark organizational transformations, setting the foundation for future application development. In practice, however, there are a number of considerations to make that go beyond simply “build, ship, and run,” which changes how...
Cloud computing delivers on-demand resources that provide businesses with flexibility and cost-savings. The challenge in moving workloads to the cloud has been the cost and complexity of ensuring the initial and ongoing security and regulatory (PCI, HIPAA, FFIEC) compliance across private and public clouds. Manual security compliance is slow, prone to human error, and represents over 50% of the cost of managing cloud applications. Determining how to automate cloud security compliance is critical...
Traditional IT, great for stable systems of record, is struggling to cope with newer, agile systems of engagement requirements coming straight from the business. In his session at 18th Cloud Expo, William Morrish, General Manager of Product Sales at Interoute, will outline ways of exploiting new architectures to enable both systems and building them to support your existing platforms, with an eye for the future. Technologies such as Docker and the hyper-convergence of computing, networking and...